Carbonic Anhydrase IX targeted radioligand therapeutics for hypoxic solid tumors

Bookmark/Download	Download as PDF
Track Code	2022-LOW-69560
Categories	Pharmaceuticals
Keywords	Carbonic anhydrase IX conjugate Pharmaceuticals Radiotherapy targeted therapy
Public Abstract	NCS: Researchers at Purdue University have discovered radiotherapeutics that target carbonic anhydrase IX (CA IX), a marker of hypoxia. Hypoxia is a common feature of solid tumors and develops because of poorly formed vasculature due to rapid growth of the tumor that outstrips the oxygen supply. Current radiotherapy treatments are non-specific and often toxic with severe side-effects. The Purdue researchers discovered small molecule ligands of CA IX to selectively bind it and deliver the radiotherapeutic. Advantages -Non-toxic -Targeted therapy Applications -Solid tumor treatment
People	Low, Philip Stewart (Project leader) Srinivasarao, Madduri
Intellectual Property	Application Date Sep 16, 2022 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Sep 24, 2021 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org